Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib in recurrent and/or metastatic salivary gland carcinomas
2010-020375-24Phase 2Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib in salivary gland cancer (SGC), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Overall response rate by RECIST. Started Jul 2010; status: completed.
02
Drugs
sorafenib
03
Conditions
salivary gland cancer (SGC)
Beyond the preview
Go deeper on 2010-020375-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020375-24.